Showing 16-20 of 34 data studies & next generation registries:
OM1 Launches Multiple Sclerosis Registry With More Than 20,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, July 14, 2021 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its multiple sclerosis (MS) registry. MS is an auto-immune, inflammatory disease that attacks the central nervous system (CNS) and causes a variety of neurological symptoms, such as muscle weakness, spasticity, fatigue, numbness, vision[…]

Black Women Less Likely To Undergo Digital Breast Tomosynthesis

M.D. Alert Published: March 5, 2021 Read the Full Commentary >> (Reuters Health) – Women have better screening outcomes with digital breast tomosynthesis, but a new study suggests that Black women have less access to this imaging modality. Researchers examined data on 385,503 women screened at one of 63 U.S. breast imaging facilities between 2015[…]

Pearls and Pitfalls in Analyzing RWD for Autoimmune Diseases

Thu. Sep 10, 2020 2:00 PM – 3:00 PM EDT Register Real-world data (RWD) is playing an increasing role in health care decisions, especially with autoimmune diseases where diagnosis can be difficult and there is no cure. Despite the promises of RWD to improve our understanding of the natural history of these diseases and to[…]

AAO-HNSF Partners With OM1 To Empower More Measured & Precise Care And Treatments For ENT

Collaboration enables otolaryngologists and researchers to leverage data for real-world evidence, outcomes, and personalized medicine programs BOSTON, May 13, 2020 — OM1, a real-world outcomes and technology company, today announced a strategic partnership with the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) connecting the Foundation’s Reg-entSM  clinical data registry to OM1’s real-world data[…]

RWD for Research & Regulatory: Collecting, Processing and Leveraging High-Quality Data

Tuesday, March 31 – 1:00 – 2:00 pm ET Register The promise of real-world data is driving increased requirements and use. But, what does high-quality RWD actually look like? How should life sciences companies access and use it most effectively? What are the implications when applying RWD to clinical trials, registries, and other evidence and[…]